Newbury Pharmaceuticals AB (OSTO:NEWBRY) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NEWBRY Newbury Pharmaceuticals AB OSTO:NEWBRY
41 GF Score
Price kr2.48
GF Value kr3.20
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Newbury Pharmaceuticals AB Valuation Rank Related Terms

OSTO:NEWBRY
41GF Score
Newbury Pharmaceuticals AB OSTO:NEWBRY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20. GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.

Key valuation signals for OSTO:NEWBRY:

  • Valuation Rank:
  • GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges P52:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for OSTO:NEWBRY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.48
Price
kr3.20
GF Value